Fauci had asked the National Institutes of Health to join the Zoom meeting to congratulate Promising for becoming the first provider to enroll a patient in a clinical trial for new coronovirus treatment. According to NIH, the findings from the study will be used to determine the effectiveness of combining antiviral drug remediation with a “highly concentrated solution of antibodies”.
An infectious diseases physician with FirstSheet, Dr. Gretchen Arnocki said the disease caused by the virus by President Donald Trump earlier this month is similar to the diagnosis of COVID-19.
“It’s the same general idea, but the way this antibody is produced is a little different from what President Trump found,” he said in a phone interview Monday. “It derives from a pool of antibodies from people who donate plasma.”
Trump’s treatment included a monoclonal antibody, a synthetic stand-in for natural antibodies generated by the human immune system. Clinical trials for a monoclonal antibody treatment developed by pharmaceutical company Eli Lilly were halted on Tuesday due to safety concerns.
The treatment being investigated by Arnocki will be delivered to a patient at Moore Regional Hospital in Pinehurst before expanding to 499 other patients in hospitals around the world. Some of these patients will receive a placebo, a practice Arnoki referred to as “incredibly standard”.
“Just about any drug you find in a pharmacy has been tested in a placebo-controlled trial,” she said. “This is common and common in a study where we are trying to prove whether something is beneficial or not.”
Study results may be available by the end of the year, according to Arnoki.
“They said they are trying to get results as soon as possible so that we know if it really works,” she said. “Once the results are in place, we can work towards making it more comprehensive therapy to make it effective.”